Phase 2 Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Brief description of study

The objectives of this study are to evaluate the efficacy and safety of an oral medication, "ALXN2050", compared to placebo and establish an effective dose that addresses ongoing unmet medical need in patients with LN or IgAN who are treated with background standard of care.

Clinical Study Identifier: s22-00142 Identifier: NCT05097989
Principal Investigator: Howard Belmont.
Other Investigator: Janine M. Sullivan.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.